Arctic Bioscience - Primary insiders who have provided bank guarantee

Reference is made to the stock exchange release from earlier today, 1 April 2026 regarding new long-term financing, including agreements with shareholders who have provided guarantees for the new financing. The following companies closely related to primary insiders are a part of the shareholders which have provided guarantees for the new financing: · Ronja Capital AS, a company closely related to Board Member Tore Tønseth, NOK 10,0 million · Vartdal Holding AS, a company closely related to Board Member Jan Endre Vartdal, NOK 1,5 million · Brødrene Vartdal AS, a company closely related to Board Member Jan Endre Vartdal, NOK 1,5 million This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19 and the Norwegian Securities Trading Act § 5-12. For more information, please contact: Christer L. Valderhaug CEO Mobile: +47 920 84 601 E-mail: christer@arctic-bioscience.com Jone R. Slinning CFO Phone: +47 948 75 469 E-mail: jone@arctic-bioscience.com About Arctic Bioscience Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds. The company is developing HRO350 - a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile. Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand. Arctic Bioscience is led by a highly skilled team of talents with diverse and highly relevant background.